By Michael Dabaie

 

Voyager Therapeutics Inc. (VYGR) shares were up 9% to $26.52 in midday trading Monday.

The clinical-stage gene therapy company said earlier it restructured its gene therapy relationship with Sanofi Genzyme.

Voyager said it is gaining world-wide rights to the VY-HTT01 Huntington's disease program and ex-U.S. rights to the VY-FXN01 Friedreich's ataxia program. Voyager is, in turn, transferring the ex-U.S. rights to VY-FXN01 to Neurocrine Biosciences Inc. (NBIX) under the terms of a collaboration agreement.

Neurocrine shares were up 2.3% to $85.82.

To focus resources on the now wholly-owned Huntington's disease program, Voyager said it would seek a partner to advance its preclinical program for SOD1 amyotrophic lateral sclerosis. Voyager said it no longer expects to file an investigational new drug application with the U.S. Food and Drug Administration for its VY-SOD102 in 2019.

 

Write to Michael Dabaie at michael.dabaie@wsj.com

 

(END) Dow Jones Newswires

June 17, 2019 13:02 ET (17:02 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Sanofi (EU:SAN)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Sanofi Charts.
Sanofi (EU:SAN)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Sanofi Charts.